Your browser doesn't support javascript.
loading
Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: Secondary analyses by baseline pain intensity and use of rescue medication of a phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial.
Viscusi, Eugene R; de Leon-Casasola, Oscar; Cebrecos, Jesús; Jacobs, Adam; Morte, Adelaida; Ortiz, Esther; Sust, Mariano; Vaqué, Anna; Gottlieb, Ira; Daniels, Stephen; Muse, Derek; Kuss, Michael E; Videla, Sebastián; Gascón, Neus; Plata-Salamán, Carlos.
Afiliación
  • Viscusi ER; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • de Leon-Casasola O; University of Buffalo/Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Cebrecos J; Esteve Pharmaceuticals S.A., Barcelona, Spain.
  • Jacobs A; Premier Research, Reading, UK.
  • Morte A; Esteve Pharmaceuticals S.A., Barcelona, Spain.
  • Ortiz E; Esteve Pharmaceuticals S.A., Barcelona, Spain.
  • Sust M; Esteve Pharmaceuticals S.A., Barcelona, Spain.
  • Vaqué A; Esteve Pharmaceuticals S.A., Barcelona, Spain.
  • Gottlieb I; Chesapeake Research Group LLC, Pasadena, Maryland, USA.
  • Daniels S; Optimal Research LLC, Austin, Texas, USA.
  • Muse D; JBR Clinical Research, Salt Lake City, Utah, USA.
  • Kuss ME; Michael Kuss Consulting, Austin, Texas, USA.
  • Videla S; Esteve Pharmaceuticals S.A., Barcelona, Spain.
  • Gascón N; Esteve Pharmaceuticals S.A., Barcelona, Spain.
  • Plata-Salamán C; Esteve Pharmaceuticals S.A., Barcelona, Spain.
Pain Pract ; 2024 Jul 02.
Article en En | MEDLINE | ID: mdl-38956758
ABSTRACT

BACKGROUND:

In the randomized, phase 3, SUSA-301 trial, celecoxib-tramadol co-crystal (CTC) provided significantly greater analgesia compared with celecoxib, tramadol, or placebo in adults with acute, moderate-to-severe, postoperative pain. This post hoc, secondary analysis further evaluated the use of rescue medication and the incidence of treatment-emergent adverse events (TEAEs).

METHODS:

Patients (N = 637) were randomized 2221 to receive oral CTC 200 mg twice daily (BID; n = 184), tramadol 50 mg four times daily (QID; n = 183), celecoxib 100 mg BID (n = 181), or placebo QID (n = 89). Post hoc analyses were conducted on the use of rescue medications up to 4 and 48 h post-study drug dose, stratified by baseline pain intensity (moderate/severe), and on the incidence of TEAEs, stratified by rescue medication use.

RESULTS:

A significantly lower proportion of patients received any rescue medication within 4 h post-study dose with CTC (49.5%) versus tramadol (61.7%, p = 0.0178), celecoxib (65.2%, p = 0.0024), and placebo (75.3%, p = 0.0001); this was also seen for oxycodone use. Fewer patients in the CTC group received ≥3 doses of rescue medication compared with the other groups, irrespective of baseline pain intensity. In patients who did not receive opioid rescue medication, CTC was associated with a lower incidence of nausea and vomiting TEAEs versus tramadol alone. In patients who received rescue oxycodone, the incidence of nausea was similar in the CTC and tramadol groups, and higher versus celecoxib and placebo.

CONCLUSION:

Celecoxib-tramadol co-crystal was associated with reduced rescue medication use and an acceptable tolerability profile compared with tramadol or celecoxib alone in adults with acute, moderate-to-severe, postoperative pain.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pain Pract Asunto de la revista: NEUROLOGIA / PSICOFISIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pain Pract Asunto de la revista: NEUROLOGIA / PSICOFISIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos